Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Medical Virology"
DOI: 10.1002/jmv.25287
Abstract: Hepatitis C virus (HCV) infection is considered as a major public health problem that, worldwide, chronically affects 170 million people. Elderly patients are more likely than younger patients to have increased duration of infection, increased… read more here.
Keywords: efficacy safety; infection; sofosbuvir daclatasvir; elderly patients ... See more keywords
Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC‐UV method designated for their pharmacokinetic study in rabbits
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmaceutical and Biomedical Analysis"
DOI: 10.1016/j.jpba.2018.05.028
Abstract: ABSTRACT Sofosbuvir (SOF) and daclatasvir (DCS) are novel, recently developed direct acting antiviral agents characterized by potent anti‐hepatitis C virus action. A fast and efficient HPLC‐UV method was developed, validated and applied for simultaneous determination… read more here.
Keywords: hepatitis; sofosbuvir daclatasvir; method; sof ... See more keywords
Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2103539
Abstract: Abstract Background This study investigated the clinical efficacy sofosbuvir/daclatasvir (SOF-DCV) in patients with COVID-19. Research design and methods PubMed, Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched for relevant… read more here.
Keywords: sofosbuvir daclatasvir; efficacy sofosbuvir; group; clinical efficacy ... See more keywords
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Antimicrobial Chemotherapy"
DOI: 10.1093/jac/dkac266
Abstract: Abstract Background The COVER trial evaluated whether nitazoxanide or sofosbuvir/daclatasvir could lower the risk of SARS-CoV-2 infection. Nitazoxanide was selected given its favourable pharmacokinetics and in vitro antiviral effects against SARS-CoV-2. Sofosbuvir/daclatasvir had shown favourable… read more here.
Keywords: sofosbuvir daclatasvir; infection; nitazoxanide sofosbuvir; sars cov ... See more keywords
Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13321
Abstract: Sofosbuvir plus daclatasvir with or without ribavirin has demonstrated a high efficacy and an acceptable safety profile in clinical trials of patients infected with genotype 2 hepatitis Cvirus (HCV); however, there are currently no real‐world… read more here.
Keywords: without ribavirin; daclatasvir; sofosbuvir daclatasvir; daclatasvir without ... See more keywords